Salarius Pharmaceuticals (SLRX) Plunges 13.24% Amid Public Offering Plans

On June 18, 2025, Salarius Pharmaceuticals (SLRX) experienced a significant drop of 13.24% in pre-market trading, marking a notable shift in investor sentiment following recent developments.

Salarius Pharmaceuticals recently announced plans for a public offering of its shares, which initially drove the stock price up by over 110%. The offering, while lacking specific details such as the number of shares or their price, includes pre-funded warrants for investors whose stakes would exceed 4.99% due to the offering. This move is seen as a strategic effort to raise capital and potentially stabilize the company's financial position.

Additionally, Salarius Pharmaceuticals was granted a listing extension by the Nasdaq Hearings Panel. This extension provides the company with more time to regain compliance with the exchange’s Equity Standard and Minimum Bid Price Requirement, offering a buffer against potential delisting. This development is crucial for maintaining investor confidence and ensuring the company's continued presence on the Nasdaq.

Despite the recent volatility, the company's financial instability, characterized by declining revenues and persistent losses, remains a concern for investors. Analysts have cited these factors as reasons for a cautious outlook on the stock, with some rating it as an underperform. The heavy trading volume associated with the recent rally highlights the heightened interest and speculation surrounding Salarius Pharmaceuticals.